Predictive methods as a powerful tool in drug discovery

被引:0
作者
Verbanac, Donatella [1 ]
机构
[1] Univ Zagreb, Sch Med, Ctr Translat & Clin Res, Zagreb 41001, Croatia
关键词
pharmaceutical industry; drug research; drug development; predictive tools; in silico screening; in vitro screening; therapeutic targets;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A development of a new drug is an extremely complex process, with average costs over $900 million and a time span upto 15 years. Regulatory hurdles are progressively higher, costs are escalating and the competition is ever tougher. All these factors drive pharmaceutical companies to shorten the Research & Development (R&D) process as much as possible. Consequently, methodologies for increasing productivity of the R&D processes become more and more important. One of them, a linear drug discovery paradigm starts from numerous genes and ends with prospectivedrugs. It consists of four inter-related building blocks that together provide a whole new platform that drives a focus on R&D efforts and commercial capabilities, on use of product and capability partnerships, on provision of customer solutions (prevention, prediction and follow-up, not just treatment), and finally on preference of organizations based on a business unit model instead of a functional one. Companies are to find a combination of these building blocks that best fits their strengths, improves returns and minimizes involved risks. Predictive methodology, together with other prediction approaches applied in drug discovery, is powerful tool that is quickly becoming more and more important, if not essential, in modern drug development. In this review, a brief description of new trends, as well as new challenges of today's drug discovery is presented from the insider perspective.
引用
收藏
页码:314 / 318
页数:5
相关论文
共 20 条
  • [1] Prospects for productivity
    Booth, B
    Zemmel, R
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) : 451 - 457
  • [2] Garnier JP, 2008, HARVARD BUS REV, V86, P68
  • [3] Gilbert J., REBUILDING BIG PHARM
  • [4] Grenet O, 2001, Pharmacogenomics J, V1, P11
  • [5] HU M, INNOVATION GAP PHARM
  • [6] JELIC D, 2010, MED CHEM RE IN PRESS
  • [7] Homology modeling of human Fyn kinase structure:: Discovery of rosmarinic acid as a new Fyn kinase inhibitor and in silico study of its possible binding modes
    Jelic, Dubravko
    Mildner, Boris
    Kostrun, Sanja
    Nujic, Krunoslav
    Verbanac, Donatella
    Culic, Ognjen
    Antolovic, Roberto
    Brandt, Wolfgang
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (06) : 1090 - 1100
  • [8] Can the pharmaceutical industry reduce attrition rates?
    Kola, I
    Landis, J
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 711 - 715
  • [9] Lippi G, 2009, BIOCHEM MEDICA, V19, P137
  • [10] Toward generating simpler QSAR models: Nonlinear multivariate regression versus several neural network ensembles and some related methods
    Lucic, B
    Nadramija, D
    Basic, I
    Trinajstic, N
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2003, 43 (04): : 1094 - 1102